New treatment for diabetic retinopathy using a low dose carbon monoxide drug
HBI-002 to Treat Diabetic Retinopathy
['FUNDING_SBIR_2'] · HILLHURST BIOPHARMACEUTICALS, INC. · NIH-10918666
This study is testing a new oral medication called HBI-002 that uses tiny amounts of carbon monoxide to help protect your eyes from damage caused by diabetic retinopathy, with the hope of offering a new treatment option to prevent vision loss for people with diabetes.
Quick facts
| Phase | ['FUNDING_SBIR_2'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | HILLHURST BIOPHARMACEUTICALS, INC. (nih funded) |
| Locations | 1 site (MONTROSE, UNITED STATES) |
| Trial ID | NIH-10918666 on ClinicalTrials.gov |
What this research studies
This research focuses on developing HBI-002, a novel oral drug that delivers low doses of carbon monoxide to treat diabetic retinopathy, a serious eye condition caused by diabetes. The study aims to advance this treatment through preclinical testing in animal models to ensure its safety and effectiveness before moving to human clinical trials. The approach is based on previous findings that low doses of carbon monoxide can protect against damage in various diseases, including diabetic retinopathy. Patients may benefit from a new therapeutic option that could prevent vision loss associated with this condition.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults with diabetic retinopathy who are at risk of vision loss.
Not a fit: Patients without diabetic retinopathy or those with other unrelated eye conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new, effective treatment option for preventing blindness in patients with diabetic retinopathy.
How similar studies have performed: Previous studies have shown promising results with low dose carbon monoxide in treating various conditions, suggesting potential for success in this novel application.
Where this research is happening
MONTROSE, UNITED STATES
- HILLHURST BIOPHARMACEUTICALS, INC. — MONTROSE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: GOMPERTS, EDWARD — HILLHURST BIOPHARMACEUTICALS, INC.
- Study coordinator: GOMPERTS, EDWARD
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Acute Respiratory Distress Syndrome, Adult Respiratory Distress Syndrome